Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3197-3206

  Gillet, Jean Pierre ^a   Calcagno, Anna Maria ^a   Varma, Sudhir ^b   Davidson, Ben ^c,d   Elstrand, Mari Bunkholt ^c   Ganapathi, Ram ^e   Kamat, Aparna A ^f   Sood, Anil K ^f   Ambudkar, Suresh V ^a   Seiden, Michael V ^g   Rueda, Bo R ^h   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e TAUSSIG CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; GLUTATHIONE PEROXIDASE 3; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADENOMATOSIS POLYPOSIS COLI GENE; ADULT; AGE DISTRIBUTION; AGED; ANTIGEN PEPTIDE TRANSPORTER 2 GENE; ARTICLE; BCL2 ASSOCIATED ATHANOGENE 3 GENE; CALCIUM BINDING PROTEIN S100A10 GENE; CANCER GRADING; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FAS LIGAND GENE; GENE EXPRESSION PROFILING; GENE FUNCTION; GLUTATHIONE PEROXIDASE 3 GENE; HIGH RISK POPULATION; HUMAN; INTEGRIN ALPHA E GENE; MAJOR CLINICAL STUDY; MATRIX METALLOPEPTIDASE 9 GENE; MITOGEN ACTIVATED PROTEIN KINASE 3 GENE; MULTIDRUG RESISTANCE; ONCOGENE; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENES, MDR; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861785200     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0056     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
3. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, et al.2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005;16 Suppl 8:viii7-viii12.
4. Landen CN Jr., Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008;26:995-1005. (Pubitemid 351398093)
5. Gillet JP, Gottesman M. Mechanisms of multidrug resistance in cancer. MultiDrug Resistance in Cancer. Zhou Jun. (Ed). Totowa, NJ: Humana Press; 2010.
6. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34. (Pubitemid 43336035)
7. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007;1775:237-62.
8. Orina JN, Calcagno AM, Wu CP, Varma S, Shih J, Lin M, et al. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther 2009;8:2057-66.
9. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, et al. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst 2010;102:1637-52.
10. Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, et al. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharmaceut 2011;8:2080-8.
11. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004;2:E108.
12. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95:14-8. (Pubitemid 36124291)
13. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009;361:170-7.
14. Gillet JP, de Longueville F, Remacle J. DualChip microarray as a new tool in cancer research. Expert Rev Mol Diagn 2006;6:295-306. (Pubitemid 44174336)
15. Gillet JP, Gottesman MM. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr Pharm Biotechnol 2011;12:686-92.
16. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9:166-80.
17. Langmann T, Mauerer R, Schmitz G. Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation. Clin Chem 2006;52:310-3. (Pubitemid 43185496)
18. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, et al. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res 2009;15: 2448-55.
19. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res 2008;68: 5478-86.
20. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009;16:521-32.
21. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005;11: 6300-10. (Pubitemid 41262961)
22. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
23. de Graeff P, Crijns AP, de Jong S, Boezen M, Post WJ, de Vries EG, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 2009;101: 149-59.
24. Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 2005;11: 5539-48. (Pubitemid 41060831)
25. Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005;15:785-92. (Pubitemid 41783082)
26. Cai KQ, Yang WL, Capo-Chichi CD, Vanderveer L, Wu H, Godwin AK, et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinog 2007;46:130-43.
27. Zhang J, Ney PA. Role of BNIP3 and NIX in cell death, autophagy, and mitophagy. Cell Death Differ 2009;16:939-46.
28. Giatromanolaki A, Koukourakis MI, Sowter HM, Sivridis E, Gibson S, Gatter KC, et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004;10:5566-71. (Pubitemid 39100497)
29. Burton TR, Henson ES, Baijal P, Eisenstat DD, Gibson SB. The pro-cell death Bcl-2 family member, BNIP3, is localized to the nucleus of human glial cells: Implications for glioblastoma multiforme tumor cell survival under hypoxia. Int J Cancer 2006;118:1660-9. (Pubitemid 43376429)
30. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003;22:4734-44. (Pubitemid 36976448)
31. Duiker EW, van der Zee AG, de Graeff P, Boersma-van Ek W, Hollema H, de Bock GH, et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010;116:549-55.
32. Chaudhry P, Srinivasan R, Patel FD. Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome. Oncol Res 2010;18:549-59.
33. Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S, et al. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep 2008;20: 1299-303.
34. Scholz C, Tampe R. The peptide-loading complex-antigen translocation and MHC class I loading. Biol Chem 2009;390:783-94.
35. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, et al. HLAclass I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 2008;14:3372-9.
36. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006;118:1963-71.
37. Cappell MS. Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol Clin North Am 2008;37:1-24. (Pubitemid 351289022)
38. Rescher U, Gerke V. S100A10/p11: family, friends and functions. Pflugers Arch 2008;455:575-82. (Pubitemid 350160469)
39. Lee WY, Su WC, Lin PW, Guo HR, Chang TW, Chen HH. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer. Oncology 2004;66:429-38. (Pubitemid 39370233)
40. Maelandsmo GM, Florenes VA, Nguyen MT, Flatmark K, Davidson B. Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites. Tumour Biol 2009;30:15-25.
41. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res 2001;61:5697-702. (Pubitemid 32769079)
42. Leygue E, Snell L, Hiller T, Dotzlaw H, Hole K, Murphy LC, et al. Differential expression of psoriasin messenger RNA between in situ and invasive human breast carcinoma. Cancer Res 1996;56: 4606-9. (Pubitemid 26338057)
43. Karbova E, Davidson B, Metodiev K, Trope CG, Nesland JM. Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma. Int J Surg Pathol 2002;10:175-80. (Pubitemid 34988511)
44. Lee HJ, Do JH, Bae S, Yang S, Zhang X, Lee A, et al. Immunohistochemical evidence for the over-expression of glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma. Med Oncol 2010;28: S522-S7.
45. Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, Righetti SC, et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 2008;7:679-87. (Pubitemid 351482150)
46. Zhao Y, Zong ZH, Xu HM. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol 2010;116: 563-71.
47. Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 2008;68:4606-13.
48. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003;63:5573-81. (Pubitemid 37139880)